SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ImmunityBio converts from Immunomedics -- Ignore unavailable to you. Want to Upgrade?


To: mannamal who wrote (969)4/23/2025 2:29:17 PM
From: Huggenberg2 Recommendations

Recommended By
CCS648
mannamal

  Read Replies (1) | Respond to of 1229
 
The question now is: Will the combination of Tislelizumab (anti-PD-1) and Anktiva surpass the effectiveness of Ivonescimab (bispecific anti-PD-1 and VEGF)? Additionally, what are the treatment costs of the two drugs compared to the monodrug?